cancel
Showing results for 
Search instead for 
Did you mean: 

BLOG: Prostate Health Index Density (PHI)

Chris_McNamara
Community Manager
Community Manager
0 0 238

Prostate Health Index Density

For some time researchers have been searching for alternative prostate cancer blood tests. Prostate-specific antigen (PSA) is still the best test that is available. Even though it only detects changes in the prostate it is also affected by factors other than prostate cancer (PCa) such as infections and an enlarged prostate (benign prostate hyperplasia). This results in several unnecessary prostate biopsies in those with rising PSAs. A PSA isoform (Protein similar to PSA) called [−2]proPSA (p2PSA) has been shown to be more specific than PSA for PCa diagnosis. Prostate Health Index (phi) was derived from a formula incorporating p2PSA, total PSA (tPSA) and free PSA (fPSA). It was approved by the United States Food and Drug Administration (FDA) in 2012 for men aged 50 or above with PSA values of 4–10 ng/ml and a normal digital rectal examination (DRE) finding. Prostate health index density includes the prostate volume measured on ultrasound. Phi has been demonstrated to be superior compared to PSA, fPSA, and PSA density in predicting PCa. In patients with a negative systematic prostate biopsy, there is still a 15–30% risk of PCa diagnosed on repeated biopsy. For this reason, continued surveillance with a PSA and DRE is important in patients with initial negative biopsies. Patient selection for a repeat biopsy is also important in order to maximize cancer detection, while avoiding unnecessary biopsy related complications.

A study by Liu et al in 2021 investigated the relationships between initial phi and phi density level and the detection of PCa and high grade PCa (HGPCa) over time with a long follow-up period in patients with initial negative prostate biopsies1. They found that patients with an initially negative prostate biopsy, a higher baseline phi level predicted an increase in PSA as well as PCa and a HGPCa diagnosis over a median follow-up period of more than 6 years. It was also observed that a higher baseline phi was associated with a higher risk of PI-RADS 4 or 5 lesions detected on subsequent MRI of the prostate. PIRADS is a classification system to grade the severity of prostate cancer on MRI (PIRADS 4 and 5 indicates high grade cancer). In men with phi < 25, 28 out of 163 men had MRI prostate at follow-up and only 1 PI-RADS 4 and no PI-RADS 5 lesion was reported. In men with phi ≥ 35, 38 out of 103 had an MRI of the prostate done, with 2 PI-RADS 4 and 7 PI-RADS 5 lesions reported. A higher phi density was significantly associated with higher risk of both PCa and HGPCa diagnosis, with phi density of ≥1.2 having a 21% risk of HGPCa compared with 0% in phi density of <0.4. 86.5% of the cohort had phi density <1.2, and among them 94.5% did not have PCa and 97.7% did not have HGPCa diagnosis on follow-up. It appears that phi density has better ability to predict men with very high and very low risks of HGPCa in the long run, and phi density cutoffs of 0.4 and 1.2 may be better than phi cutoffs for guiding the subsequent need for investigations. Phi density has been reported to be associated with clinically significant PCa on biopsy and radical prostatectomy specimens in other studies. Using phi or phi density can effectively stratify the risk of PCa and HGPCa diagnosis over 6 years. For men with lower initial phi or phi density with one negative prostate biopsy, the next follow-up PSA testing can be performed at least a few years later. On the other hand, for men with higher phi (≥35) or phi density (≥1.2), more aggressive follow-up investigation including more frequent PSA blood taking, MRI and/or repeated biopsy should be performed to avoid delayed diagnosis of HGPCa. Therefore, phi and phi density could guide follow-up plans of patients with a prior negative biopsy. Men with phi density ≥1.2 predicted an increasing PSA trend of +0.95 ng/ mL/year, while those with phi density <1.2 had a relatively static course. Therefore, men with one negative biopsy and a baseline phi density of ≥1.2 will likely have a higher risk of rapid rise in PSA.  

This is the first study of its kind to investigate the role of baseline phi and phi density in predicting future PCa risk. Self reported limitations of the study include its retrospective nature. Not all men received a pre biopsy MRI so all biopsies at baseline were systematic TRUS biopsies which can lead to underdiagnosis of cancers in a proportion of men at initial biopsy. Not every man had a follow-up biopsy or MRI prostate, and undiagnosed cancers might exist in the cohort. The authors observed that men without a re-biopsy were mainly men in the lower baseline phi groups with static PSA over almost 6.5 years, and the risk of significant cancer in this cohort (with previous negative biopsy and a static PSA over a long time period) would be exceedingly low.

PHI is already a part of the European Association of Urology cancer guidelines and PHI density may have broader clinical utility in the near future. In summary men with a prior negative prostate biopsy, a higher phi (≥35) or phi density (≥1.2) will need closer follow-up and repeated investigation, while men with lower phi (<25) or phi density (<0.4) with minimal HGPCa risk could have less frequent follow-up.

Reference

  1. Liu AQ, Remmers S, Lau S et al. Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study. Nature: Prostate Cancer and Prostatic Diseases 2021.

 

Chris_McNamara_0-1642036823951.jpeg

 

 

 

 About the Author

Kalli Spencer

MBBCh, FC Urol (SA), MMed (Urol), Dip.Couns (AIPC)

Kalli is an internationally renowned Urological Surgeon, specialising in oncology and robotic surgery. He trained and worked in South Africa, before relocating to Australia where he has worked at Macquarie University Hospital and Westmead Hospital. His passion for what he does extends beyond the operating room, through public health advocacy, education and community awareness of men’s health, cancer and sexuality.

Kalli has been involved with the Prostate Cancer Foundation of Australia for many years, advocating for improved cancer care and facilitating community prostate cancer support groups.

 
 
 
Help is Available
 

Prostate Cancer Specialist Telenursing Service:

If your life has been impacted by prostate cancer, our Specialist Telenursing Service is available to help. If you would like to reach out to the PCFA Prostate Cancer Specialist Telenurse Service for any questions you have about your prostate cancer experience, please phone 1800 22 00 99 Monday - Friday 9am - 5pm, Wednesday 10am-8pm (AEST).

 

Prostate Cancer Support Groups:

PCFA is proud to have a national network of affiliated support groups in each state and territory of Australia consisting of men and women who have a passion for assisting others who encounter prostate cancer. This network is made up of over 170 affiliated groups who meet locally to provide one-to-one support, giving a vision of life and hope after treatment. Call us on 1800 22 00 99 to find your local group.

 

MatesCONNECT Telephone-based peer support:

MatesCONNECT is a telephone-based peer support program for men affected by prostate cancer. If you’ve recently been diagnosed with prostate cancer, our MatesCONNECT service can connect you to a trained volunteer who understands what you’re going through. All of our volunteers have been through prostate cancer. Simply call us on 1800 22 00 99 to be connected with a volunteer.

 

Newly diagnosed? or need to find more information -Access the PCFA resources here!

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.